Treatment for eye lesions in children with plasminogen deficiency
Management of Recurrent and Progressive Ligneous Conjunctivitis Due to Plasminogen Deficiency. An N of One Clinical Trial of Topical Administration of Allogenic Plasma to Affected Eye
This study is testing if applying donor plasma to the eyes can help children with plasminogen deficiency prevent eye lesions that can cause vision problems.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 1 (estimated) |
| Ages | 1 Month to 18 Years |
| Sex | All |
| Sponsor | University of Saskatchewan Academic / other |
| Locations | 1 site (Saskatoon, Saskatchewan) |
| Trial ID | NCT05404932 on ClinicalTrials.gov |
What this trial studies
This study aims to treat recurrent ligneous conjunctivitis in children with congenital plasminogen deficiency using aliquoted allogenic plasma. The treatment involves applying donor plasma to the eyes multiple times a day for a duration of 2 to 6 months, depending on the severity of the condition and the patient's response. The goal is to prevent the recurrence of pseudomembranous lesions that can lead to vision loss and other complications. The study will enroll one patient at the University of Saskatchewan.
Who should consider this trial
Good fit: Ideal candidates for this study are children under 18 years old diagnosed with plasminogen deficiency and experiencing ocular involvement.
Not a fit: Patients who are 18 years or older or do not have plasminogen deficiency or ocular manifestations will not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve eye health and prevent blindness in children suffering from plasminogen deficiency.
How similar studies have performed: While this approach is based on existing clinical data showing the effectiveness of plasminogen replacement, the specific use of allogenic plasma for this condition is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients under the age of 18 years * Diagnosis of plasminogen deficiency (Definition: clinical presence of pseudomembranous lesions and serum plasminogen level \< 50%) * Ocular involvement (Ligneous Conjunctivitis) due to plasminogen deficiency Exclusion Criteria: * Patient is 18 years or older * Patients with no plasminogen deficiency * Patients with no ocular manifestations of plasminogen deficiency
Where this trial is running
Saskatoon, Saskatchewan
- University of Saskatchewan — Saskatoon, Saskatchewan, Canada (Recruiting)
Study contacts
- Study coordinator: Sarah Tehseen, MBBS MSc.
- Email: sarah.tehseen@saskhealthauthority.ca
- Phone: 639-998-3972
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.